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Crosstalk between BRCA-Fanconi anemia and
mismatch repair pathways prevents
MSH2-dependent aberrant DNA damage responses
Min Peng1, Jenny Xie1, Anna Ucher2, Janet Stavnezer2 & Sharon B Cantor1,*
Abstract
Several proteins in the BRCA-Fanconi anemia (FA) pathway, such
as FANCJ, BRCA1, and FANCD2, interact with mismatch repair
(MMR) pathway factors, but the significance of this link remains
unknown. Unlike the BRCA-FA pathway, the MMR pathway is not
essential for cells to survive toxic DNA interstrand crosslinks (ICLs),
although MMR proteins bind ICLs and other DNA structures that
form at stalled replication forks. We hypothesized that MMR
proteins corrupt ICL repair in cells that lack crosstalk between
BRCA-FA and MMR pathways. Here, we show that ICL sensitivity of
cells lacking the interaction between FANCJ and the MMR protein
MLH1 is suppressed by depletion of the upstream mismatch recog-
nition factor MSH2. MSH2 depletion suppresses an aberrant DNA
damage response, restores cell cycle progression, and promotes
ICL resistance through a Rad18-dependent mechanism. MSH2
depletion also suppresses ICL sensitivity in cells deficient for
BRCA1 or FANCD2, but not FANCA. Rescue by Msh2 loss was
confirmed in Fancd2-null primary mouse cells. Thus, we propose
that regulation of MSH2-dependent DNA damage response under-
lies the importance of interactions between BRCA-FA and MMR
pathways.
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Introduction
DNA interstrand crosslinks (ICLs) induce a range of cellular
responses, including recruitment of DNA repair proteins to the
lesion and/or a stalled replication fork. Subsequent processing of
ICLs and restart of replication forks require the coordination of
several repair pathways, including homologous recombination
(HR) and the error-prone DNA damage tolerance mechanism,
translesion synthesis (TLS; Sale, 2012). Cells derived from
Fanconi anemia (FA) patients or BRCA1/2-associated tumors that
lack the BRCA-FA pathway (BRCA-FA cells) are extremely sensi-
tive to agents such as mitomycin C (MMC) that induce ICLs
(Moldovan & D’Andrea, 2009; Muniandy et al, 2010). This inter-
strand crosslink (ICL) sensitivity and associated chromosomal
aberrations are key determinants to diagnosing genetic deficiency
in the BRCA-FA pathway, which has up to 16 components
(Sharma & Canman, 2012).
The ICL sensitivity in BRCA-FA cells has been attributed to
defects in the repair of intermediates of ICL processing such as DNA
double-strand breaks (DSBs; Moldovan & D’Andrea, 2009). In
particular, loss of the BRCA-FA proteins BRCA1 and FANCD2 leads
to defects in recombination-directed repair. This has been attributed
to non-homologous end-joining (NHEJ) proteins that occupy the
ends of broken DNA and interfere with DNA end-processing
required for HR (Bunting & Nussenzweig, 2010; Aly & Ganesan,
2011). In FANCD2-deficient cells, the NHEJ protein DNA-PKcs is
aberrantly phosphorylated (Adamo et al, 2010). Furthermore, in
BRCA1-deficient cells, HR is restored by elimination of the NHEJ
factor, 53BP1 (Bouwman et al, 2010; Bunting et al, 2010; Aly &
Ganesan, 2011). Remarkably, loss of 53BP1 also overcomes early
embryonic lethality in BRCA1-nullizigous mice (Cao et al, 2009;
Bouwman et al, 2010; Bunting et al, 2012), suggesting that 53BP1
underlies the proliferation defect in BRCA1 mice.
While elimination of NHEJ can normalize growth and HR defects
in BRCA-FA cells, ICL repair is not fully restored. For example, in
Brca1-null mouse cells, eliminating NHEJ restored HR, but did not
fully restore ICL resistance (Bunting et al, 2012). Moreover, in
Fancd2-null mouse cells, ICL sensitivity was enhanced by inactiva-
tion of NHEJ and mice had more severe developmental defects
(Houghtaling et al, 2005; Bunting et al, 2012). Furthermore, in
worms that are mutant for the FANCJ (BACH1/BRIP1) homologue,
dog-1, ICL sensitivity was not suppressed by eliminating
NHEJ (Adamo et al, 2010). Failure to restore ICL repair in BRCA-FA
cells by suppression of NHEJ suggests that the BRCA-FA pathway
has additional roles besides suppression of NHEJ. Other functions
include protecting replication forks from degradation by nucleases
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(Schlacher et al, 2011, 2012) and orchestrating replication restart
through HR, TLS, and other post-replication repair pathways (Kim &
D’Andrea, 2012).
The functional relevance is not fully understood; however,
several reports have linked the BRCA-FA pathway with proteins of
the mismatch repair (MMR) pathway. In particular, BRCA1,
FANCD2, SLX4/FANCP, and FANCJ interactions with MMR proteins
have been reported (Wang et al, 2000; Svendsen et al, 2009;
Kratz et al, 2010; Liu et al, 2010; O’Donnell & Durocher, 2010;
Shereda et al, 2010; Smogorzewska et al, 2010; Yoshikiyo et al,
2010; Huang et al, 2011; Williams et al, 2011; Ward et al, 2012;
Peng et al, 2007). Moreover, we found that FANCJ binding to the
MMR protein MLH1 is essential for ICL repair (Peng et al, 2007;
Cantor & Xie, 2010; Xie et al, 2010). Further suggesting a functional
connection between these pathways, MMR proteins activate the
BRCA-FA pathway, including the promotion of FANCD2 monoubiq-
uitination (Huang et al, 2011; Williams et al, 2011) and also localize
FANCJ to sites of ICLs and DNA crosslinks induced by ultraviolet
light (Suhasini et al, 2013; Guillemette et al, 2014).
Proteins of the MMR pathway bind DNA lesions/perturbations
through either the heterodimer MutSb (composed of MSH2 and
MSH3) orMutSa (composed ofMSH2 andMSH6), which subsequently
recruit the MutLa complex (composed of MLH1 and PMS2; Duckett
et al, 1996; Brown et al, 1997; Yamada et al, 1997; Zhang et al, 2002;
Wu & Vasquez, 2008). When processing certain DNA lesions, such as
ICLs, MMR complexes from bacteria to human cells have been associ-
ated with break induction and promoting apoptosis (Fram et al, 1985;
Nowosielska & Marinus, 2005; Zhang et al, 2007; Fink et al, 1996;
Nehme et al, 1997). This DNA damage response could result from
MMR proteins binding ICLs or other DNA structures that form at
stalled DNA replication forks. MMR proteins also have genome
surveillance functions that counteract error-prone bypass pathways
essential for ICL processing (Jiricny, 2006; Sharma & Canman, 2012).
Here, we considered the hypothesis that MMR-dependent
responses in the absence of coordination with the BRCA-FA path-
way are detrimental and contribute to defects in FA cells. To interro-
gate the contribution of MMR to ICL processing defects, we
eliminated MMR. We found defects were suppressed by loss of
MSH2. MSH2 depletion does not appear to enhance DNA repair, but
rather attenuates the DNA damage response that is abnormally
increased in FA cells. Reduction of these responses through MSH2
depletion also correlates with the restart of DNA replication. These
findings have important clinical implications for BRCA-FA mutation
carriers, as MSH2 inactivation might propel tumor formation or
reduce the efficacy of platinum therapies used to treat BRCA-FA
pathway-associated cancers.
Results
Loss of MSH2, but not MLH1 or NHEJ proteins, reduces the MMC
sensitivity of cells deficient in FANCJ
The diversity of MMR functions in ICL processing, including activa-
tion of the BRCA-FA pathway and converting ICLs into breaks
(Fram et al, 1985; Nowosielska & Marinus, 2005; Zhang et al, 2007;
Huang et al, 2011; Williams et al, 2011), suggests that pathway
coordination is essential. To test the idea that MMR is toxic in the
absence of coordination with the BRCA-FA pathway, we tested
whether the ICL sensitivity of FANCJ-deficient cells is due to MMR
factors. We used siRNA reagents to disrupt upstream and down-
stream MMR complexes, through MSH2 or MLH1 depletion, respec-
tively. When siRNAs to FANCJ and MLH1 or MSH2 were used in
combination or alone, knockdown was achieved (Fig 1A). The
reduction in FANCJ expression resulted in the expected sensitivity
to MMC as compared to control (Fig 1B). Furthermore, MMR
depletion was sufficient to promote hyper-resistance to the DNA
methylating agent methylnitrosourea (MNU; Brown et al, 1997;
Supplementary Figure S1A) indicating the siRNAs decreased the
function of these proteins. Strikingly, as compared to FANCJ deple-
tion, FANCJ and MSH2 co-depletion enhanced MMC resistance,
whereas FANCJ and MLH1 co-depletion did not (Fig 1B and Supple-
mentary Figure S1B). Substantiating these findings, a similar result
was obtained in A549 cells with shRNA reagents targeting a distinct
MSH2 site (Supplementary Figure S1C–E), indicating that these
results were not likely to be cell type specific or the result of off-
target effects.
To further validate these findings, we examined a pair of cell
lines derived from a colon cancer patient, HEC59 (MSH2-deficient)
and HEC59+chr2 (MSH2-proficient). HEC59 cells do not express
MSH2 unless chromosome 2 is re-introduced (Fig 1C; Umar et al,
1997). We found that treatment of HEC59+chr2 cells with either of
two individual FANCJ siRNAs (a or b) resulted in sensitivity to
MMC as compared to treatment with control siRNA (Fig 1D). In
contrast, MSH2-deficient HEC59 cells depleted of FANCJ exhibited
the same levels of survival after MMC treatment comparable to
controls. Altogether, these findings indicate that MSH2 contributes
to the ICL sensitivity of FANCJ-deficient cells.
In light of recent studies in which elimination of the NHEJ
factors, DNA-PKcs or 53BP1 reduced ICL sensitivity in BRCA-FA
cells (Adamo et al, 2010; Bunting & Nussenzweig, 2010; Aly &
Ganesan, 2011), we asked whether loss of these NHEJ factors also
reduced ICL sensitivity in FANCJ-deficient cells. For these studies,
we exploited the human M059K (DNA-PKcs proficient) and M059J
(DNA-PKcs deficient) glioblastoma cell lines (Anderson et al, 2001).
Treatment of the M059K or M059J cells with two different FANCJ
siRNAs resulted in sensitivity to MMC (Fig 1E and F). Likewise,
treating the two stably 53BP1-depleted cell lines with FANCJ siRNA
resulted in MMC sensitivity (Fig 1G and H). Thus, eliminating or
depleting DNA-PKcs or 53BP1 does not suppress MMC sensitivity
associated with FANCJ deficiency, consistent with findings in
Caenorhabditis elegans (Adamo et al, 2010).
MSH2 depletion suppresses ICL sensitivity in cells lacking the
FANCJ–MLH1 interaction
FANCJ binds directly to MLH1, and cells expressing a FANCJ
mutant that cannot bind MLH1 are hypersensitive to MMC (Peng
et al, 2007). Thus, we hypothesized that a function of the interac-
tion was to inhibit the action of MSH2 at lesions induced by MMC.
Immunoblot and co-immunoprecipitation experiments of FA-J-null
(FA-J) patient cell lines confirmed that FANCJK141/142A was
expressed similarly to FANCJWT, but was defective in MLH1 binding
(Fig 2A). As expected, FA-J cells complemented with FANCJK141/142A
remained sensitive to MMC, whereas FA-J cells complemented with
wild-type FANCJ had enhanced resistance (Fig 2B; Peng et al,
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2007). Consistent with a rescue from MMC sensitivity, siRNA to
MSH2 increased MMC resistance 3.6-fold in FA-J cells expressing
the FANCJK141/142A mutant (Fig 2C–E). In contrast, siRNA for MLH1
had no effect on MMC resistance in the FANCJK141/142A FA-J cell
lines, indicating again that with respect to rescue from MMC sensi-
tivity, MLH1 is distinct from MSH2.
In contrast to FA-J cells complemented with FANCJK141/142A,
MSH2 depletion had only a small effect on FA-J cells complemented
with vector (Fig 2D and E) and did not enhance MMC resistance in
FA-J cells expressing a helicase inactivating mutant FANCJK52R
(Supplementary Figure S2B). These findings suggest that MSH2
depletion rescues the repair defect in cells in which FANCJ cannot
bind to MLH1, but does not rescue loss of a FANCJ function(s)
connected to its helicase activity. Perhaps MSH2 depletion is able to
rescue FANCJ-depleted cells because there is sufficient residual heli-
case activity (Fig 1B and Supplementary Figure S1B).
MSH2 depletion rescues aberrant checkpoint and DNA damage
responses in cells lacking the FANCJ–MLH1 interaction
FA cells also have prolonged checkpoint responses and exacerbated
DNA damage responses that are thought to contribute to the growth
defects, ICL sensitivity, and bone marrow failure in FA patients
(Ceccaldi et al, 2012; Kim & D’Andrea, 2012). The prolonged G2/M
arrest in FA cells has been analyzed in response to ICL-inducing
agents such as MMC or melphalan (Litman et al, 2005). We previ-
ously found that FA-J cells have a prolonged G2/M accumulation in
response to melphalan that is corrected by introduction of
FANCJWT, but not the MLH1 binding mutant, FANCJK141/142A (Peng
et al, 2007; Supplementary Figure S3). Moreover, as compared to
vector, FANCJK141/142A complemented FA-J cells have a more
pronounced G2/M accumulation (Peng et al, 2007; Supplementary
Figure S3). Thus, we asked whether these cell cycle recovery defects
were also attributable to MSH2. While MSH2 depletion had only a
modest effect on FA-J cells with vector, and little or no effect on
FANCJWT, the prolonged G2/M accumulation was reduced in FA-J
cells with FANCJK141/142A (Fig 3A and B), suggesting that MSH2
contributes to the ICL-induced checkpoint defect in cells lacking the
FANCJ–MLH1 interaction.
The exacerbated DNA damage response in FA cells includes
hyper-phosphorylation of the NHEJ protein, DNA-PKcs (Adamo
et al, 2010). To address whether MSH2 contributes to this DNA
damage response, we generated FA-J cells with FANCJK141/142A and
shRNA to MSH2 or control using vectors that also express green
fluorescent protein (GFP). Cells positive for GFP and containing
shRNA to MSH2 had markedly reduced MMC-induced DNA-PKcs
phosphorylation relative to cells expressing shRNA control vector
(Fig 3C). Immunoblot analysis revealed a similar reduction in phos-
phorylation of DNA-PKcs and that MMC treatment induced a
damage response evidenced by phosphorylated H2AX, c-H2AX,
albeit slightly less in the MSH2-depleted cells (Fig 3D). These find-
ings suggest that MSH2 mediates aberrant activation of NHEJ,
perhaps by inducing DSBs in response to MMC.
Because NHEJ contributes to ICL-induced chromosomal aberra-
tions in FA cells (D’Andrea & Grompe, 2003), we next tested
whether MSH2 depletion limited the number or type of aberrations
found in FA-J cells lacking the FANCJ–MLH1 interaction. Remark-
ably, we found fewer radial chromosomes and chromosomes with
breaks induced by MMC treatment in the FANCJK141/142A-comple-
mented FA-J cells expressing shMSH2 than in cells expressing
control shRNA (shCon; Fig 3E). Cells expressing control shRNA had
~9 chromosomal aberrations per mitotic spread as compared to ~4 in
cells expressing MSH2 shRNA (Fig 3F). Collectively, these findings
indicate that MSH2 contributes to the MMC sensitivity, prolonged
G2/M accumulation, hyper-activation of DNA-PKcs, and radial
chromosomes in FA-J cells lacking the FANCJ–MLH1 interaction.
MSH2 depletion could promote survival of MMC-treated cells by
enhancing recombination-based repair. To address this possibility,
FANCJK141/142A-expressing FA-J cells positive for c-H2AX foci were
analyzed for co-staining Rad51 foci. At all time points examined, we
found that cells positive for c-H2AX foci have a similar percent of
Rad51 foci whether they express shRNA control or MSH2 shRNA
vectors (Fig 4A and B, and Supplementary Figure S4A). Moreover,
at several time point post-MMC, the chromatin bound Rad51
appeared similar and c-H2AX was induced in both cell lines at 16 h
post-MMC (Fig 4C). While c-H2AX was slightly reduced by 24 h
post-MMC in MSH2-depleted FANCJK141/142A-FA-J cells as compared
to control FA-J cells, more striking was the reduction in phosphory-
lated RPA and DNA-PKcs (Fig 4D and Supplementary Figure S4B
and C). Thus, MSH2 does not appear to alter the accumulation of
Rad51, perhaps at resected DNA sites prior to ICL excision (Long
et al, 2011), but may contribute to ICL-induced break formation.
MSH2 depletion reduces MMC sensitivity through a
Rad18-dependent mechanism
The restart of stalled replication forks by TLS was shown to mediate
the reduced cytotoxicity of cisplatin in MMR-deficient cells (Lin et al,
Figure 1. Sensitivity to mitomycin C (MMC) in FANCJ-deficient cells is suppressed by loss of MSH2, but not MLH1, DNA-PKcs, or 53BP1.
A Immunoblot analysis of FANCJ, MLH1, and MSH2 expressions in U2OS cells treated with indicated siRNAs. b-actin was used as a loading control.
B Graph shows the percentage of viable cells 5 days after indicated dose of MMC.
C Immunoblot analysis of FANCJ and MSH2 expressions in human MSH2-null (HEC59) and MSH2-proficeint (HEC59+Chr2) cell lines treated with indicated siRNA
reagents to Con or FANCJ (a or b).
D Graph shows the percentage of viable cells 5 days after 500 nM MMC.
E Immunoblot analysis of FANCJ and DNA-PKcs in DNA-PKcs-deficient (M059J) and DNA-PKcs-proficient (M059K) cells treated with siRNA reagents to Con or FANCJ (a
or b).
F Graph shows the percentage of viable cells 5 days after 250 nM MMC.
G Immunoblot analysis showing 53BP1 or FANCJ expression in U2OS cells stably expressing shRNA vectors to either control or 53BP1 (a or b) that were also transfected
with siRNAs to Con or FANCJ.
H Graph shows the percentage of viable cells 5 days after 250 nM MMC.
Data information: Where shown, error bars represent standard deviations from three independent experiments.
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2006). TLS requires PCNA ubiquitination by the Rad18/Rad6 ubiqu-
itin–ligase complex (Kannouche & Lehmann, 2004; Alt et al, 2007;
Waters et al, 2009). Thus, we tested whether the gains in MMC
resistance due to MSH2 depletion in the FANCJK141/142A-comple-
mented FA-J cells are dependent on Rad18. When siRNAs and
shRNAs to Rad18 or MSH2 were used in combination or alone,
knockdown was achieved (Fig 4E). Compared with MSH2 depletion
alone, MSH2 and Rad18 co-depletion reduced MMC resistance (Fig 4F).
Furthermore, gain in MMC resistance in MSH2-deficient HeLa cells
was also dependent on Rad18 (Supplementary Figure S5A–D).
Depleting Rad18 or the TLS polymerase REV1 also sensitized MCF7
or U20S cells co-deficient in FANCJ and MSH2 (Supplementary
Figure S5E and F). These findings suggest that in a non-cell-type-
specific manner, MSH2 depletion promotes MMC resistance through a
Rad18-dependent mechanism that requires TLS polymerases such as
REV1.
MSH2 depletion restores replication restart after
aphidicolin-induced arrest
Processing of ICLs is complex and involves lesion processing, repair,
and the restoration of replication fork progression. By simply arrest-
ing cells with the DNA polymerase inhibitor aphidicolin, we sought
to gain clarity as to the underlying defect in cells lacking the
FANCJ–MLH1 interaction. Moreover, it was previously shown that
defects in S phase progression characterize FANCJ-deficient cells
following release from aphidicolin (Greenberg et al, 2006; Kumara-
swamy & Shiekhattar, 2007). Similar to treatment with MMC,
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Figure 2. Mitomycin C (MMC)-induced sensitivity in cells lacking the FANCJ–MLH1 interaction is suppressed by MSH2 depletion.
A Immunoblot analysis of FANCJ and/or MLH1 in the indicated Fanconi anemia (FA)-J complemented cell lines from whole-cell extracts or following
immunoprecipitation.
B Graph shows the percentage of viable cells 5 days after increasing doses of MMC.
C Immunoblot analysis of FANCJ, MSH2, and MLH1 expressions in the FA-J cell lines treated with the indicated siRNAs.
D, E Graphs show the percentage of viable cells 5 days after increasing doses of MMC (D) or as compared at one dose (E).
Data information: Where shown, error bars represent standard deviations from three independent experiments. The asterisk (*) represents a P-value < 0.01.
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Figure 3. Aberrant DNA damage responses in cells lacking the FANCJ–MLH1 interaction are suppressed by MSH2 depletion.
A Immunoblot analysis of FANCJ and MSH2 expressions in the Fanconi anemia (FA)-J cell lines expressing indicated shRNAs.
B Representative cell cycle profiles based on PI staining of DNA content for the indicated FA-J cell lines untreated (U) or at the indicated times following 0.25 lg/ml
melphalan treatment.
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D Immunoblot analysis with indicated antibodies.
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treatment with aphidicolin correlated with an aberrant induction of
DNA-PKcs phosphorylation in FA-J cells lacking FANCJWT (Fig 5A
and Supplementary Figure S6A). Correspondingly, FA-J cells lacking
FANCJWT were severely defective in S phase progression following
release from aphidicolin and did not incorporate Edu in a 1-h pulse
(Fig 5B and C). Notably, as compared to vector, FANCJK141/142A-
complemented FA-J cells had an even more severe defect and did
not recover by 48 h, but rather required from 72 to 96 h to gain a
4N DNA population (Fig 5D and data not shown), indicating that
cells lacking the FANCJ–MLH1 interaction have a pronounced defect
in resuming cell cycle progression. By analyzing the percent of G2/
M cells following aphidicolin release, we found that MSH2 depletion
effectively restored cell cycle progression to the FANCJK141/142A-
expressing FA-J cells (Fig 5E) consistent with MSH2 interfering with
the restart of stalled replication forks when cells lack the FANCJ–
MLH1 interaction (see model in Supplementary Figure S7).
MSH2 depletion reduces MMC sensitivity in human cells deficient
in FANCJ, FANCD2, or BRCA1, but not FANCA
To determine whether MSH2 underlies aberrant responses in other
BRCA-FA cells, we tested whether MSH2 contributed to MMC sensi-
tivity in cells lacking BRCA-FA proteins known to interact with
MMR proteins, such as BRCA1 or the central FA pathway protein,
FANCD2 (Wang et al, 2000; Williams et al, 2011). We also tested
whether MSH2 contributed to MMC sensitivity in cells lacking the
FA upstream core component, FANCA, which has not been shown
to interact with MMR proteins. As expected, U2OS cells treated with
siRNA reagents to FANCJ, FANCD2, FANCA, or BRCA1 were more
sensitive to MMC than cells treated with control siRNA (Fig 6A and
B, blue bars). Similar to our results in FANCJ-deficient cells, BRCA1-
or FANCD2-deficient U2OS cells treated with siRNAs to MSH2 have
improved survival after MMC treatment as compared to cells treated
with siRNA controls (Fig 6B, red bars, Supplementary Figure S8A).
Furthermore, the MMC sensitivity of BRCA1-depleted MCF7 cells
was fully suppressed by MSH2 depletion (Supplementary Figure
S8B and C). In contrast, the MMC sensitivity of FANCA-deficient
U2OS or FA-A patient cells depleted of MSH2 was not suppressed
(Fig 6A and B, and Supplementary Figure S8D–G), suggesting
FANCA functions in ICL processing in a manner distinct from
FANCJ, BRCA1, or FANCD2.
DNA-PKcs is aberrantly phosphorylated in FANCD2-deficient
cells in response to MMC (Adamo et al, 2010), similar to our find-
ings in FANCJ mutant cells (Fig 3C and D). Thus, we asked whether
MSH2 contributed to this aberrant response in FANCD2-deficient
cells, as it does in FANCJ mutant cells. Indeed, FA-D2 patient cells
stably expressing shRNA GFP-fusion vectors to MSH2 show mark-
edly less MMC-induced DNA-PKcs phosphorylation than cells
expressing shRNA control vector after MMC treatment (Fig 6C and D).
In addition, MSH2-depleted FA-D2 cells as compared to control
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FA-D2 cells had a reduction in the phosphorylation of DNA-PKcs
(Fig 6E), suggesting that MSH2 contributes to the abnormal DDR in
FANCD2-deficient cells.
Msh2 deletion reduces MMC sensitivity and the DNA damage
response in Fancd2-null mouse cells
To substantiate these findings, we analyzed the impact of deleting
Msh2 in Fancd2-null mouse embryonic fibroblasts (MEFs). When
mice heterozygous for Fancd2 and Msh2 were interbred and
embryos were harvested between 13 and 14 days of gestation, we
identified double-mutant embryos, which upon visual inspection
resembled wild-type embryos. From 86 embryos, we obtained four
double mutants (Fig 7A). We found that compared with wild-type,
the fancd2/ MEFs were extremely sensitive to MMC, with only
22% of cells surviving after treatment with 25 nM MMC. We also
found that resistance to MMC was enhanced in double-knockout
MEFs to a level comparable with wild-type (Fig 7B), indicating that
ICL sensitivity is reduced by Msh2 deletion as previously found for
Mlh1 deletion (van de Vrugt et al, 2009).
To further ascertain whether FA-like phenotypes found in
Fancd2-null MEFs were suppressed by msh2 deletion, we analyzed
the DNA damage response. Compared with wild-type MEFs, MMC
induced a greater damage response in fancd2/ MEFs, as detected
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by an antibody to ATR/ATM-phosphorylated substrates and
c-H2AX, consistent with a previous report (Ceccaldi et al, 2012).
These phosphorylation events were reduced in the fancd2/
msh2/ MEFs (Fig 7C and D). Next, we analyzed 53BP1 foci,
which mark unrepaired lesions remaining due to problems during
replication (Lukas et al, 2011). As reported in FANCD2-deficient
human cells (Ceccaldi et al, 2012) and FANCM-deficient cells
(Blackford et al, 2012), we found more 53BP1 foci in the fancd2/
MEFs than in wild-type MEFs. And here too, we detected fewer
53BP1 foci in the fancd2/msh2/ MEFs (Fig 7E and F). Together,
these findings suggest that Msh2 contributes to ICL sensitivity and
the heightened DNA damage response in Fancd2-null cells.
Discussion
The BRCA-FA and MMR pathways intersect through several protein
interactions. FANCD2-FAN1, BRCA1, and FANCJ interact with
MLH1, and SLX4/FANCP interacts with MSH2 (Wang et al, 2000;
Svendsen et al, 2009; Kratz et al, 2010; Liu et al, 2010; O’Donnell &
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Durocher, 2010; Shereda et al, 2010; Smogorzewska et al, 2010;
Yoshikiyo et al, 2010). Moreover, the MMR pathway activates the
BRCA-FA pathway, inducing FANCD2 monoubiquitination and
localization of FANCJ to sites of DNA crosslinks (Huang et al, 2011;
Williams et al, 2011; Suhasini et al, 2013; Guillemette et al, 2014).
In this study, we provide further evidence that crosstalk between
BRCA-FA and MMR pathways is critical for coordinating the DNA
damage response. In particular, we find that lack of coordination
between these pathways, as in BRCA-FA cells, makes MSH2 toxic.
Consistent with this point, ICL sensitivity is suppressed by MSH2
depletion in human cells deficient in the FANCJ–MLH1 interaction,
FANCJ, or other BRCA-FA proteins, such as BRCA1 or FANCD2 that
interact with MMR proteins (Figs 1B, 2D and E). Also, eliminating
the MMR pathway in Fancd2-deficient mouse cells suppresses ICL
sensitivity (Fig 7B; van de Vrugt et al, 2009), whereas loss of NHEJ
does not (Houghtaling et al, 2005; Bunting et al, 2012). Interest-
ingly, MSH2 depletion fails to rescue FANCA-deficient cells (Fig 6B
and Supplementary Figure S8D–G). Thus, in a distinct set of BRCA-
FA pathway deficient cells, loss of MMR function could synergize
and contribute to tumors in FA patients.
Our data indicate that in the absence of BRCA-FA and MMR path-
way coordination, MSH2 exacerbates the DNA damage response
that characterizes FA cells. In particular, FA cells have a dysregulated
NHEJ pathway in which DNA-PKcs is hyper-phosphorylated in
response to DNA damage (Adamo et al, 2010). Aberrant DNA
damage responses also include hyper-induction of ATR/ATM signal-
ing pathways (Lukas et al, 2011; Ceccaldi et al, 2012), which were
apparent in the Fancd2-null MEFs following MMC (Fig 7C and D).
Even in unperturbed Fancd2-null MEFs, 53BP1 foci are enhanced,
suggesting replication stress (Fig 7E and F; Lukas et al, 2011). Signif-
icantly, these aberrant DNA damage responses are suppressed by
MSH2 loss (Fig 7C–F). Phosphorylation of DNA-PKcs is associated
with its binding to DNA double-strand breaks (Meek et al, 2004).
Therefore, DSB induction is likely a consequence of MSH2 activity in
FA cells treated with MMC. In agreement, inhibiting MMR reduces
the number of DSBs at stalled forks and promotes ICL resistance
through enhanced recombination and TLS bypass pathways (Brown
et al, 1997; Durant et al, 1999; Moreland et al, 1999; Wu et al, 2004;
Lin et al, 2006). Likewise, we found that bypass pathways are essen-
tial for the mechanism of ICL resistance in MSH2-depleted cells
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(Fig 4F and Supplementary Figure S5B–G). Thus, we propose that
eliminating MSH2 and its associated DNA damage response
enhances ICL resistance through bypass pathways.
Our results also indicate that MSH2 depletion does not dramati-
cally improve Rad51-based repair. We did not find evidence that
recombination was heightened, as MMC-induced Rad51 foci and
chromatin loading did not change upon MSH2 deletion (Fig 4B and C).
In support of MSH2 blocking a restart step in ICL processing,
when FANCJ mutant cells are arrested by aphidicolin, we also find
induction of DNA-PKcs phosphorylation and defects in the restart of
DNA replication (Fig 5A–C). Upon MSH2 depletion, however,
mutant FA-J cells progress to G2/M (Fig 5E). Interestingly, MSH2
deficiency abolishes the anticancer and pro-aging activity of short
telomeres by reversing proliferative defects, but not by enhancing
recombination (Martinez et al, 2009). Thus, we suggest that in cells
deficient for FANCJ, BRCA1, or FANCD2, MSH2 loss improves the
ability of stalled forks to restart, but does not increase DNA repair.
The finding that MSH2-, but not MLH1-depletion rescues cells
deficient for FANCJ or the FANCJ–MLH1 interaction (Figs 1B and
2D) suggests that FANCJ functions with MLH1 to prevent corrup-
tion/blockage of ICL repair by MSH2. Conceivably, FANCJ helicase
and/or translocase activities could displace MSH2 heterodimers or
unwind DNA structures that are substrates for MSH2. Of note,
MSH2 binds branched DNA structures associated with replication
forks (Alani et al, 1997; Kolodner & Marsischky, 1999), including
G4 DNA structures that are substrates for FANCJ unwinding (Larson
et al, 2005; Wu et al, 2009; Sarkies et al, 2012). Thus, to temper an
MSH2 DNA damage response, FANCJ could restrict MSH2 heterodi-
mers in several ways. First, to promote ICL repair, FANCJ might
remove MSH2 bound to ICLs. Second, to promote error-prone
recombination or TLS extension reactions that are required for ICL
processing (Sharma & Canman, 2012), FANCJ might remove MSH2
that is bound to DNA mismatches. Finally, to restart replication
following ICL processing, FANCJ might similarly prevent MSH2
binding to secondary structures that form at arrested forks that are
barriers to replication. Unwinding DNA substrates and/or displacing
MSH2 could explain the role of FANCJ in coupling replication past
fork barriers (Schwab et al, 2013). The ability of FANCJ to
dismantle MSH2 could underlie the importance of the FANCJ–MLH1
interaction for ICL repair as MLH1 links FANCJ to the MSH2 hetero-
dimer (Peng et al, 2007). We suspect that the relevant heterodimer
displaced is MSH2–MSH6. This conclusion is not based on MSH6
depletion studies because MSH6 siRNAs also reduced MSH2 expres-
sion (Supplementary Figure S9), and thus, the experiment would be
uninformative. However, MSH3 depletion did not alter MSH2 or
MSH6 levels, and we found that MMC resistance was not enhanced
(Supplementary Figure S9).
Aside from functioning with MLH1 to limit MSH2, our data
suggest that FANCJ has a separate helicase function that is also
important for ICL repair. Most notably, MSH2 depletion has little or
no effect on FANCJ-null cells or cells that lack FANCJ helicase activity
(Supplementary Figure S2B). This further supports the hypothesis
that FANCJ functions with MLH1 to remove MSH2 from a DNA
lesion, perhaps with its translocase activity, and also unwinds DNA
barriers with its helicase activity. As compared to FANCJ-null cells,
cells lacking the FANCJ–MLH1 interaction have a more severe ICL
processing defect (Peng et al, 2007; Fig 3B) and a more severe
replication restart defect following arrest by aphidicolin treatment
(Fig 5D), suggesting that stalled replication forks are differentially
processed (see model in Supplementary Figure S7). We speculate
that stalled replication forks remain intact in FANCJ-null cells, a
point supported by studies in DT40 cells (Schwab et al, 2013).
Restart at these forks likely involves loss of genomic integrity,
consistent with loss of G4 structures in FANCJ-null cells (Cheung
et al, 2002; London et al, 2008; Wu et al, 2008; Sarkies et al, 2012).
Replication barriers could be cleaved by opportunistic nucleases
that gain access to stalled forks, as found in BRCA-FA cells
(Schlacher et al, 2011, 2012). Instead, in cells lacking the FANCJ–
MLH1 interaction, replication barriers could be insurmountable.
FANCJ could physically block nucleases and MSH2 could in turn
block FANCJ. Thus, restart via nucleases and break induction fails
and forks collapse. This model suggests that in FANCJK141/142A
mutant cells, MSH2 depletion, but not MLH1, will ‘unlock’ the
secondary structure and enable FANCJ to unwind the replication
barrier and restart replication. In FANCJ-null cells, MSH2 depletion
has little effect because without FANCJ helicase activity, the replica-
tion barrier remains and restart will be largely dependent on
nucleases. In sum, MSH2 depletion may rescue cells that have
FANCJ helicase activity (FANCJK141/142A FA-J), but not cells without
FANCJ helicase activity (vector or FANCJK52R FA-J cells). Rescue
may be achieved in FANCJ siRNA-depleted cells because sufficient
residual FANCJ supports its helicase function.
FANCD2-deficient cells are effectively rescued by loss of MSH2
(Figs 6 and 7) or by loss of MLH1 when p53 is also inactivated (van
de Vrugt et al, 2009). While MLH1 loss alone did not rescue cells
deficient for FANCJ or the FANCJ–MLH1 interaction, we did not
address if co-depletion of p53 would. Any differences could reflect
the fact that some BRCA-FA proteins function with MMR complexes
to initiate the DNA damage response aside from a role in regulating
MMR. Indeed, FANCD2 forms complexes with MMR proteins at
several nodes. FANCD2 binds MLH1 (Huang et al, 2011; Williams
et al, 2011), and following DNA damage, the monoubiquitinated
FANCD2 is found in a complex containing the MLH1-associated
endonuclease FAN1 (Kratz et al, 2010; Smogorzewska et al, 2010).
To process ICLs, FAN1 is predicted to function with other endonuc-
leases, such as SLX4, that associate with MSH2 (Kim & D’Andrea,
2012). Thus, FANCD2 and associated partners could serve to link
upstream and downstream MMR complexes. In FANCJ-deficient
cells, in which FANCD2 undergoes a normal DNA damage-induced
monoubiquitination (Litman et al, 2005), MLH1 loss could be
insufficient to disarm an MSH2–SLX4–FANCD2–FAN1-dependent
DNA damage response.
Our study indicates that MSH2 depletion rescues a subset of
BRCA-FA cells, FANCJ-, BRCA1-, and FANCD2-deficient, but not
FANCA-deficient cells. Notably, MSH2 loss also does not restore ICL
resistance to FANCM-null DT40 cells (Huang et al, 2011). This
distinction could reflect that FANCJ, BRCA1, and FANCD2 function
at least in part through their MMR protein interactions, whereas to
our knowledge, FANCA and FANCM do not interact with MMR
proteins. BRCA1 and FANCD2, similar to FANCJ, could restart repli-
cation through MMR protein interactions that serve to dismantle
MSH2. By contrast, FANCA and FANCM could contribute to replica-
tion restart by engaging bypass pathways. Indeed, FANCM is
required for template switch mechanisms (Whitby, 2010; Blackford
et al, 2012). Likewise, FANCA through complex formation with
REV1 activates bypass pathways (Kim et al, 2012; Fig 6F). A
The EMBO Journal Vol 33 | No 15 | 2014 ª 2014 The Authors
The EMBO Journal MSH2 is toxic without BRCA-FA and MMR crosstalk Min Peng et al
1708
Published online: June 25, 2014 
fundamental role in bypass pathways could explain why MSH2
depletion fails to rescue.
Taken together, these findings are relevant for understanding FA
disease and progression to cancer. FA patient hematopoietic stem
and progenitor cells have a hyperactivated DNA damage response
that is dampened in transformed FA cells (Ceccaldi et al, 2012).
Determining whether this abnormal DNA damage response and/or
the progression to bone marrow failure in FA patients are generated
by MMR factors that promote a barrier to tumorigenesis will be an
important future research direction. If so, loss of MMR could predict
the onset of tumorigenesis in patients. Moreover, it will be impor-
tant to identify whether MMR inactivation or suppression will be
useful for therapy to retard the progression to bone marrow failure.
Materials and Methods
Cell culture
MCF7, HeLa, A549, and U2OS cells were grown in DMEM supple-
mented with 10% fetal bovine serum and penicillin/streptomycin
(100 U/ml each). M059J and M059K cells were cultured in DMEM/
F12 (1:1) supplemented with 10% fetal bovine serum and antibiot-
ics. Human endometrial HEC59 and HEC59+chr2 cell lines, FA-J
(EUFA30-F), FA-D2 (PD20), and FA-A (PD6914) cell lines were
cultured in DMEM supplemented with 15% fetal bovine serum.
FA-J cells were infected with the POZ retroviral vectors as described
in Nakatani & Ogryzko (2003). Generation of FANCJWT, FANCJK52R,
FANCJK141/142A, and pOZ vectors and stable FA-J cell lines was
described (Peng et al, 2007). Stable shRNA cells were selected with
puromycin.
siRNA and shRNA
siRNA transfections were carried out with Lipofectamine RNAiMax
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. Analyses were performed 48–72 h after siRNA transfec-
tion. siRNA reagents for MSH2 (siRNA MSH2 pool, target sequence
of (a) GAAGAGACCUUAACUAUGC, or (b) GGAGGUAAAUCAA-
CAUAUA), MLH1 (siRNA MLH1 smartpool), Rad18 (siRNA Rad18
smartpool), FANCD2 (siRNA FANCD2 smartpool), BRCA1 (siRNA
BRCA1 smartpool), FANCA [siRNA FANCA smartpool or two
distinct siRNA, target sequence of (a) AGAGGAAGAUGUUCA-
CUUAUU, or (b) GGACAUCACUGCCCACUUCUU)], and luciferase
(Luc) were obtained from Dharmacon (Lafayette, CO, USA). The
FANCJ siRNA reagents were described previously (Litman et al,
2005). U2OS, FA-D2, or FA-J stable cells were infected with pGIPZ
vectors expressing GFP and containing shRNAs against non-silenc-
ing control, MSH2 (a) (mature antisense sequence, CATGTAATA-
GAGTGTGCTA) or MSH2 (b) (ATTACTTCAGCTTTTAGCT), 53BP1
(a) (mature antisense sequence, AGCAGCAACCCAGACTATA), or
53BP1 (b) (AGAAGTAGAAAGAAAAGTA), MSH6(a) (mature anti-
sense sequence, TTCAACTCGTATTCTTCTGGC) or MSH6(b)
(mature antisense sequence, TTTCAACTCGTATTCTTCTGG), MSH3
(a) (mature antisense sequence, ATGACCTTATTCCTTCTGTGC) or
MSH3(b) (mature antisense sequence, TTCCCTTAATTTAAG-
GAGTGG). shRNAs were obtained from the UMMS shRNA core
facility.
Cell growth and cell cycle analysis
Cells were seeded into six-well plates, incubated overnight, and left
untreated or treated with MMC (Sigma, St Louis, MO, USA) for 1 h
and CPT for 5 h (Invitrogen). Cells treated with MNU (1 h, serum
free) were first pre-treated with 20 lM O6-benzylguanine (O6-BZG)
to block methylguanine methyltransferase (MGMT). In addition,
O6-BZG was also included during and after treatment. Cells were
counted after 5 days using a hemocytometer and compared with
untreated controls, and cell survival was analyzed as before (Xie
et al, 2010). FA-J stable cell lines were either mock-treated or
treated with 0.25 lg/ml of melphalan (Sigma) or 18 h with aphidoc-
olin (3 lg/ml; Sigma) at which time fresh media was introduced.
Cells were collected at various times and fixed with 90% methanol
in PBS overnight and then incubated 10 min with PBS containing
30 lg/ml DNase-free RNase A and 50 lg/ml propidium iodide.
1 × 104 cells were analyzed using a FACSCalibur instrument
(Becton-Dickinson, San Jose, CA, USA). Aggregates were gated
out, and the percentage of cells in G2/M was calculated using
ModFit software. Errors represent standard deviation of the mean.
Statistical analysis was performed using Student’s two-tailed,
unpaired t-test.
Western blot and antibodies
Cells were harvested, lysed, and processed for immunoblot analysis
as described previously using an NETN lysis buffer (20 mM Tris,
150 mM NaCl, 1 mM EDTA, and 0.5% NP-40) containing 10 mM
NaF and 1 mM NaVO3 (Litman et al, 2005). Antibodies for Western
blot analysis included FANCJ (E67), BRCA1 (ms110) (Cantor et al,
2004), MLH1 (Santa Cruz), MSH2 (Calbiochem), 53BP1 (Novus
Biologicals), FANCD2 (FARF), FANCA (FARF), DNA-PKcs Ser2056
(Abcam), phospho RPA32 (S4/S8) (Bethyl), RPA32 (Bethyl), DNA-
PKcs (Biolegend), MCM-7 (Abcam), c-H2AX (Millipore), Rad18
(Abcam), Rad51 (Santa Cruz), MSH6 (BD Bioscience), MSH3 (BD
Bioscience), and b-actin (Sigma). Chromatin preparations were
carried out with NE-PER Nuclear and Cytoplasmic Extraction
Reagents kit (Thermo Scientific) according to the manufacturer’s
instructions. The ratio of phospho-protein to total protein was
measured and quantified using ImageJ software.
Immnuofluorescence
Immunofluorescene was performed as described previously (Cantor
et al, 2001). Cells grown on cover slips were either untreated or
treated with MMC (250 nM) for 16 h. Then, cells were fixed and
permeabilized. After incubation with primary antibodies against
phospho DNA-PKcs (Abcam; 1:200), c-H2AX (Upstate 1:100),
Rad51 (Abcam; 1:1,000), 53BP1 (Novus Biologicals; 1:100), or
P-ATR/ATM Substrate (Cell Signaling; 1:100), cells were washed
and then incubated with secondary antibody. After washing, cover
slips were mounted onto glass slides using Vectashield mounting
medium containing DAPI (Vector Laboratories). Cells with > 10
foci per cell were scored as positive. For Edu labeling, cells were
left untreated or treated with aphidocolin for 18 h and released
at indicated times. Edu labeling was carried out with Click-iT
Edu imaging kit (Invitrogen) according to the manufacturer’s
instructions.
ª 2014 The Authors The EMBO Journal Vol 33 | No 15 | 2014
Min Peng et al MSH2 is toxic without BRCA-FA and MMR crosstalk The EMBO Journal
1709
Published online: June 25, 2014 
Metaphase spread preparation
Cells were left untreated or treated with MMC. Then, cells were
incubated in media containing 100 ng/ml Colcemid for 1.5 h. After
incubation, cells were harvested by trypsinization, lysed in 75 mM
KCl, and fixed with fixative solution (75% methanol, 25% acetic
acid). Fixed cells were dropped onto slides at 55°C, allowed to dry,
and stained with Giemsa. Chromosome abnormalities were scored
based on standard guidelines (Levitt et al, 2007).
Generation of mice and PCR genotyping
Msh2-deficient mice (Reitmair et al, 1996) were obtained from T.
Mak, University of Toronto, Toronto, Canada. Fancd2-deficient mice
(Houghtaling et al, 2003) were obtained from M. Grompe, Oregon
Health and Sciences University, Portland, OR, USA. The mouse
strains were backcrossed to C57BL/6 for at least eight generations.
Mice were maintained as heterozygotes, and double heterozygotes
(Msh2+/Fancd2+/) were bred to obtain embryos of all six geno-
types studied here. Mice were housed in the same room of the
IACUC-approved SPF facility at University of Massachusetts Medical
School and were bred and used under guidelines formulated by the
University of Massachusetts Animal Care and Use Committee. As
described in Reitmair et al, 1996 and Houghtaling et al, 2003, 50 ng
of gDNA was prepared from embryo’s head or mom’s tail and used
as a template in PCR to genotype mice. For Fancd2, forward primer
MG968 (50-TCAGCCTCACATGGAGTTTAACG-30) and two reverse
primers MG1280 (50-GCTACACAGCATTGCCCATAAAG-30) and
MG1008 (50-CAGGGATGAAAGGGTCTTACGC-30) were used to
amplify a wild-type band of 303 bp or a mutant band of 459 bp. The
reaction conditions were 95°C for 2 min; 36 cycles of 94°C for 25 s,
58°C for 25 s, and 72°C for 35 s; and a final extension at 72°C for
2 min. For Msh2, forward primer Msh2 COM (50-AAAGTGCACGT-
CATTTGGA-30) and two reverse primers Msh2 WT (50-GCTCACTTA-
GACGCCATTGT-30) and Msh2 MT (50-GCCTTCTTGACGAGTTCTTC-
30) were used to amplify a wild-type band of 174 bp or a mutant
band of 460 bp. The reaction conditions were 95°C for 2 min; 36
cycles of 94°C for 30 s, 62°C for 30 s, and 72°C for 30 s; and a final
extension at 72°C for 7 min.
Supplementary information for this article is available online:
http://emboj.embopress.org
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